Australia's most trusted
source of pharma news
Posted 29 November 2021 AM
Health Minister Greg Hunt used the last round of PBS listing announcements for 2021 to declare AbbVie's Venclexta will be reimbursed from December 1 for Australians suffering acute myeloid leukaemia (AML).
Venclexta will be expanded for adults with newly diagnosed AML for use in combination with azacitidine for those patients who are ineligible for intensive chemotherapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.